MOGA 2018 Conference Review - reviewed by Conjoint Professor Michael Friedlander AM

In this review:

Patient preference for 3 or 6 months of adjuvant chemotherapy for colon cancer
Association between mGSTP1 DNA levels and response to docetaxel in mCRPC
Pembrolizumab vs. placebo after complete resection in high-risk stage 3 melanoma
Preoperative ctDNA predicts outcome in resectable stage 3 melanoma
Avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy
Health-related QOL with pembrolizumab vs. placebo in metastatic NSCLC
CARG vs. oncologists’ estimates for predicting chemotherapy toxicity in older adults
Changing first-line treatment landscape for mCRPC
What oncologists tell patients with incurable cancer

Please login below to download this issue (PDF)

Subscribe